Technology

Key publications published by the scientific founding team.
 

Key publications

Lenogue K, Walencik A,  Laulagnier K, Molens J.-P, Benlalam H, Dreno B, Coulie P, Pule M, Chaperot L, Plumas J. Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells. Vaccines, 2021 Feb; 9, vaccines-09-00141-v2.pdf

Charles J, Chaperot L, Hannani D, Bruder Costa J, Templier I, Trabelsi S, Gil H, Moisan A, Persoons V, Hegelhofer H, Schir E, Quesada J-L, Mendoza C, Aspord C, Manches O, Coulie P G, Khammari A, Dreno B, Leccia M-T& Plumas J. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. OncoImmunology, 2020 Apr; 9:1, An innovative plasmacytoid dendritic cell line based cancer vaccine primes and expands antitumor T cells in melanoma patients in a first in human.pdf 

Charles J, Chaperot L, Revol B, Baudin M, Mouret S, Hamon A, Leccia MT, Plumas J, Aspord C. The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. Pigment Cell Melanoma Res. 2018 Jan;31(1):82-94. https://doi.org/10.1111/pcmr.12618

Martinet J, Leroy V, Dufeu-Duchesne T, Larrat S, Richard MJ, Zoulim F, Plumas  J, Aspord C. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology. 2012 Nov;56(5):1706-18.  https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.25879

Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, Plumas J. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. J Invest Dermatol. 2012 Oct;132(10):2395-2406. https://doi.org/10.1038/jid.2012.152

Aspord C, Laurin D, Richard MJ, Vie H, Chaperot L, Plumas J. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Am J Transplant. 2011 Dec;11(12):2613-26. https://doi.org/10.1111/j.1600-6143.2011.03722.x

Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R, Lefebvre C, Plumas J, Leccia MT, Chaperot L. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol. 2010 Jun;130(6):1646-56. https://doi.org/10.1111/j.1600-6143.2011.03722.x  

Aspord C, Charles J, Leccia MT, Laurin D, Richard MJ, Chaperot L, Plumas J. A  novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PLoS One. 2010 May 4;5(5):e10458. https://doi.org/10.1371/journal.pone.0010458 

Charles J, Chaperot L, Salameire D, Di Domizio J, Aspord C, Gressin R, Jacob MC, Richard MJ, Beani JC, Plumas J, Leccia MT. Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol. 2010 Jan-Feb;20(1):16-23. doi: 10.1684/ejd.2010.0816

Lui G, Manches O, Angel J, Molens JP, Chaperot L, Plumas J. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS One. 2009 Sep 22;4(9):e7111. https://doi.org/10.1371/journal.pone.0007111

Di Domizio J, Blum A, Gallagher-Gambarelli M, Molens JP, Chaperot L, Plumas J. TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of  early IFN-inducible genes in the absence of type I IFN. Blood. 2009 Aug 27;114(9):1794-802. https://doi.org/10.1182/blood-2009-04-216770